I had to "reassign" one of my GA tonight just for @pipjon but so many great contributions to the thread for this announcement.
Re EUR CDMO time will tell, expect a lot of speculation until the July/August strategic update but for the drug development moving preparing for commercialisation phase wouldn't be surprised if there was a collaboration/partnership (these take many forms, not just lambo buyouts) of sorts being worked out that needs to be announced at the right time. What are your thoughts @Boffin99 ?
Given the disadvantages of the standard of care central line CVC there should be a lot of interest from BP on the new formula & delivery pharmacokinetics.
Drug development trials is an area I need to revisit as I spent more time jumping ahead to the marketing modules instead.
Ann: H1 2023 Preclinical and Clinical Programs Update, page-68
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |